Arrowhead Pharmaceuticals: RNA interference Medication Plozasiran Lowers Triglycerides in Dyslipidemia
Patients with familial chylomicronemia syndrome (FCS) treated with plozasiran demonstrated a maximum reduction of 98% in triglyceride levels at month ...